The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | Promising novel antibody therapies for AML
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares an update on the most promising novel antibody therapies for the treatment of acute myeloid leukemia (AML). Dr Ravandi discusses CD33- targeting antibodies, in particular gemtuzumab ozogamicin, and other promising targets, such as CD123. Dr Ravandi also outlines the potential benefits of bispecific T-cell engagers such as flotetuzumab, AMG 330, AMG 673, AMG 472 and vibecotamab (XmAb14045). This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
